Back to Search
Start Over
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
- Source :
- Leukemia, Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, 35 (6), pp.1597-1609. ⟨10.1038/s41375-020-01009-z⟩, Leukemia, Vol. 35, no. 6, p. 1597-1609 (2020)
- Publication Year :
- 2020
-
Abstract
- International audience; Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10-5) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD
- Subjects :
- 0301 basic medicine
Male
Cancer Research
Neoplasm, Residual
MESH: Immunotherapy
Chronic lymphocytic leukemia
Gastroenterology
MESH: Clinical Trials, Phase III as Topic
0302 clinical medicine
Bone Marrow
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
MESH: Leukemia, Lymphocytic, Chronic, B-Cell
MESH: Aged
education.field_of_study
[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology
Hematology
MESH: Follow-Up Studies
Prognosis
3. Good health
Fludarabine
Survival Rate
Leukemia
MESH: Antineoplastic Combined Chemotherapy Protocols
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
MESH: Vidarabine
MESH: Bone Marrow
Female
MESH: Rituximab
Immunotherapy
Rituximab
MESH: Clinical Trials, Phase II as Topic
Vidarabine
medicine.drug
medicine.medical_specialty
Cyclophosphamide
MESH: Survival Rate
Population
[SDV.CAN]Life Sciences [q-bio]/Cancer
MESH: Prognosis
03 medical and health sciences
Clinical Trials, Phase II as Topic
Chemoimmunotherapy
Internal medicine
medicine
Humans
education
Survival rate
MESH: Neoplasm, Residual
Aged
Retrospective Studies
MESH: Humans
business.industry
MESH: Cyclophosphamide
MESH: Retrospective Studies
medicine.disease
Leukemia, Lymphocytic, Chronic, B-Cell
MESH: Male
body regions
030104 developmental biology
Clinical Trials, Phase III as Topic
Bone marrow
business
MESH: Female
Follow-Up Studies
Subjects
Details
- ISSN :
- 14765551 and 08876924
- Volume :
- 35
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Leukemia
- Accession number :
- edsair.doi.dedup.....3c17eb6ada5bc62c0f087f0102c524ab
- Full Text :
- https://doi.org/10.1038/s41375-020-01009-z⟩